Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$4.12B |
| 2 |
Gilead Sciences
GILD
|
+$379M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$286M |
| 4 |
Amazon
AMZN
|
+$271M |
| 5 |
Meta Platforms (Facebook)
META
|
+$266M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$762M |
| 2 |
SPDR Gold Trust
GLD
|
+$410M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$400M |
| 4 |
QIHU
QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS
QIHU
|
+$227M |
| 5 |
Synchrony
SYF
|
+$195M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 91.35% |
| 2 | Consumer Staples | 2.31% |
| 3 | Technology | 1.26% |
| 4 | Financials | 1.12% |
| 5 | Healthcare | 1.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
6226
CALL
State Street SPDR Dow Jones International Real Estate ETF
RWX
$263M
| $455K | ﹤0.01% |
10,900
+4,300
| +65% | +$181K |
|
|
ONC
6227
BeOne Medicines Ltd
ONC
$41.5B
| $455K | ﹤0.01% |
+14,758
| New | +$429K |
|
|
SIR
6228
PUT
DELISTED
SELECT INCOME REIT
SIR
| $455K | ﹤0.01% |
38,448
-13,877
| -27% | -$165K |
|
6229
Invesco S&P Global Water Index ETF
CGW
$1.06B
| $454K | ﹤0.01% |
+14,701
| New | +$446K |
|
|
CLNY
6230
CALL
DELISTED
Colony Capital, Inc.
CLNY
| $454K | ﹤0.01% |
24,900
-34,100
| -58% | -$604K |
|
6231
Community Trust Bancorp
CTBI
$1.39B
| $453K | ﹤0.01% |
12,200
| – | – |
|
6232
Expeditors International
EXPD
$24.8B
| $453K | ﹤0.01% |
8,800
-94,998
| -92% | -$4.81M |
|
6233
CALL
MiMedx Group
MDXG
$656M
| $453K | ﹤0.01% |
52,800
-14,900
| -22% | -$118K |
|
|
VRN
6234
DELISTED
Veren
VRN
| $453K | ﹤0.01% |
+34,341
| New | +$512K |
|
6235
Allient
ALNT
$1.58B
| $452K | ﹤0.01% |
35,864
-18,940
| -35% | -$270K |
|
6236
PUT
Banco Bilbao Vizcaya Argentaria
BBVA
$160B
| $452K | ﹤0.01% |
77,204
+45,732
| +145% | +$264K |
|
6237
Lakeland Financial Corp
LKFN
$1.48B
| $452K | ﹤0.01% |
12,750
-7,662
| -38% | -$265K |
|
|
MAG
6238
PUT
DELISTED
MAG Silver
MAG
| $452K | ﹤0.01% |
30,000
-5,800
| -16% | -$91.4K |
|
|
TIME
6239
DELISTED
Time Inc.
TIME
| $452K | ﹤0.01% |
31,200
-112,462
| -78% | -$1.7M |
|
6240
PUT
ProShares UltraShort FTSE Europe
EPV
$9.51M
| $451K | ﹤0.01% |
1,780
-8,900
| -83% | -$2.36M |
|
6241
CALL
Oceaneering
OII
$5.04B
| $451K | ﹤0.01% |
16,400
-36,100
| -69% | -$999K |
|
|
ECHO
6242
PUT
EchoStar
ECHO
$25.2B
| $451K | ﹤0.01% |
+12,710
| New | +$403K |
|
|
FMK
6243
DELISTED
First Trust Mega Cap AlphaDEX Fund
FMK
| $451K | ﹤0.01% |
16,600
-29,313
| -64% | -$792K |
|
6244
PUT
Coherus Oncology
CHRS
$218M
| $450K | ﹤0.01% |
+16,800
| New | +$458K |
|
6245
Ross Stores
ROST
$73.3B
| $450K | ﹤0.01% |
7,000
-43,265
| -86% | -$2.66M |
|
|
RP
6246
DELISTED
RealPage, Inc.
RP
| $450K | ﹤0.01% |
17,522
+8,563
| +96% | +$213K |
|
6247
CALL
Haemonetics
HAE
$4.73B
| $449K | ﹤0.01% |
12,400
+3,800
| +44% | +$130K |
|
|
MZTI
6248
PUT
The Marzetti Company
MZTI
$3.13B
| $449K | ﹤0.01% |
+3,400
| New | +$444K |
|
6249
PUT
UBS Group
UBS
$168B
| $449K | ﹤0.01% |
33,000
-66,900
| -67% | -$911K |
|
|
AMAG
6250
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
| $449K | ﹤0.01% |
18,300
-9,600
| -34% | -$240K |
|
Similar funds
Jeff Yass's Q3 2016 Portfolio in Review
As of Q3 2016, Jeff Yass held 9,816 positions worth $207B, up 11% from $187B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jeff Yass's Q3 2016 filing shows 1,347 new, 3,278 increased, 3,435 reduced and 1,488 closed positions. Its largest new stake was Bristol-Myers Squibb: 4,459,411 shares worth $240M. The largest sale was Apple, an estimated $762M.
By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Technology.
- Jeff Yass's largest Q3 2016 buy was Bristol-Myers Squibb: 4,459,411 shares worth $240M.
- Jeff Yass added most to Procter & Gamble in Q3 2016, an estimated $4.12B increase.
- Jeff Yass's biggest Q3 2016 reduction was Apple, cutting an estimated $762M.
- Jeff Yass fully exited QIHOO 360 TECHNOLOGY CO LTD ADS RPSTG 3 CL A SHS in Q3 2016, selling an estimated $227M.
- Jeff Yass's ten largest holdings make up 27% of its $207B portfolio in Q3 2016.
- Jeff Yass opened 1,347 new positions and closed 1,488 in Q3 2016.
- Jeff Yass's portfolio value rose 11% quarter-over-quarter to $207B.
Based on Susquehanna International Group's 13F filing for Q3 2016, filed 14 Nov 2016.